Possible synergism of physical exercise and ghrelin-agonists in patients with cachexia associated with chronic heart failure

Aging Clinical and Experimental Research

Volumn 26, Issue 4, 2014, Pages 341-351

  Invernizzi, M ^a   Carda, S ^b   Cisari, C ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cachexia; Chronic heart failure; Ghrelin; Ghrelin agonists; Physical exercise

Indexed keywords

GHRELIN; GHRELIN AGONIST; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

ANOREXIA; CACHEXIA; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOCRINE DISEASE; EXERCISE; FOOD INTAKE; GROWTH HORMONE RELEASE; HEART FAILURE; HEART PROTECTION; HUMAN; INOTROPISM; MALNUTRITION; MUSCLE CELL; NEUROENDOCRINOLOGY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYMPATHETIC TONE; AGONISTS; ANIMAL; CHRONIC DISEASE; COMPLICATION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CACHEXIA; CHRONIC DISEASE; EXERCISE; GHRELIN; HEART FAILURE; HUMANS;

EID: 84915793162     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-013-0186-7     Document Type: Review

References (126)

1. Mant J, Al-Mohammad A, Swain S, Larame P, Guideline Development Group (2011) Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline. Ann Intern Med 155:252-259
2. American Heart Association (2005) Heart disease and stroke statistics: 2005 Update. American Heart Association, Dallas, Texas. http://my.clevelandclinic.org/Documents/heart/11053909 18119HDSStats2005Update.pdf
3. Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22:1527-1560
4. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ (2001) More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 3:315-322
5. Haehling S, Lainscak M, Springer J (2009) Anker SD Cardiac cachexia: a systematic overview; von. Pharmacol Ther 121:227-252
6. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491-497
7. Fearon KC (1992) The Sir David Cuthbertson Medal Lecture 1991 The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 51:251-265
8. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D et al (2008) Cachexia: a new definition. Clin Nutr 27:793-799
9. Anker MS, von Haehling S, Springer J, Banach M, Anker SD (2013) Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Int J Cardiol 162:73-76
10. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M (1996) Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing 25:144-149
11. Anker SD, Steinborn W, Strassburg S (2004) Cardiac cachexia. Ann Med 36:518-529
12. Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P (1994) Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 121:860-862
13. Obisesan TO, Toth MJ, Donaldson K, Gottlieb SS, Fisher ML, Vaitekevicius P et al (1996) Energy expenditure and symptom severity in men with heart failure. Am J Cardiol 77:1250-1252
14. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W et al (2001) Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 38:443-452
15. Schols AM, Deutz NE, Mostert R, Wouters EF (1993) Plasma amino acid levels in patients with chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 48:546-548
16. Oudemans-van Straaten HM, Bosman RJ, Treskes M, van der Spoel HJ, Zandstra DF (2001) Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med 27:84-90
17. Herrmann M, Taban-Shomal O, Hubner U, Bohm M, Herrmann W (2006) A review of homocysteine and heart failure. Eur J Heart Fail 8:571-576
18. Gorelik O, Almoznino-Sarafian D, Feder I, Wachsman O, Alon I, Litvinjuk V et al (2003) Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 99:177-181
19. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236-241
20. Mann DL (2001) Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 6:71-80
21. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S (1994) Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89:955-958
22. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S (1994) Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72:561-566
23. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D et al (1998) Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391-398
24. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ (1997) Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79:1426-1430
25. Sharma R, Bolger AP, Rauchhaus M, von Haehling S, Doehner W, Adcock IM et al (2005) Cellular endotoxin desensitization in patients with severe chronic heart failure. Eur J Heart Fail 7:865-868
26. Jankowska EA, von Haehling S, Czarny A, Zaczynska E, Kus A, Anker SD et al (2005) Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure. Eur J Heart Fail 7:984-990
27. von Haehling S, Doehner W, Anker SD (2007) Nutrition, metabolism and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73:298-309
28. Inui A (1999) Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59:4493-4501
29. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD (1994) Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 8:1298-1308
30. Cicoira M, Kalra PR, Anker SD (2003) Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 9:219-226
31. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F et al (1997) Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30:527-532
32. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO et al (2005) Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46:1019-1026
33. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
34. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ et al (1997) Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18:621-645
35. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T et al (2000) Ghrelin, a novel growth hormonereleasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255-4261
36. Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H et al (2002) Ghrelin is present in pancreatic alphacells of humans and rats and stimulates insulin secretion. Diabetes 51:124-129
37. Mori K, Yoshimoto A, Takaya K, Hosoda K, Ariyasu H, Yahata K et al (2000) Kidney produces a novel acylated peptide, ghrelin. FEBS Lett 486:213-216
38. Gualillo O, Caminos J, Blanco M, Garcia-Caballero T, Kojima M, Kangawa K et al (2001) Ghrelin, a novel placental-derived hormone. Endocrinology 142:788-794
39. Hosoda H, Kojima M, Matsuo H, Kangawa K (2000) Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279: 909-913
40. Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS et al (2003) Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 278:8877-8880
41. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI et al (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977
42. McKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS et al (1997) Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol 11:415-423
43. Sun Y, Wang P, Zheng H, Smith RG (2004) Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101:4679-4684
44. Kojima M, Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85:495-522
45. Hansen TK, Ankersen M, Raun K, Hansen BS (2001) Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett 11:1915-1918
46. McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS et al (1995) Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc Natl Acad Sci USA 92:11165-11169
47. Tannenbaum GS, Epelbaum J, Bowers CY (2003) Interrelationship between the novel peptide ghrelin and somatostatin/ growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 144:967-974
48. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559
49. Gibney J, Healy ML, Sonksen PH (2007) The growth hormone/ insulin- like growth factor-I axis in exercise and sport. Endocr Rev 28:603-624
50. Velloso CP (2008) Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol 154:557-568
51. LeRoith D (2008) Clinical relevance of systemic and local IGFI: lessons from animal models. Pediatr Endocrinol Rev 5:739-743
52. Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, Matsuyama A et al (2004) Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150:447-455
53. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C et al (2001) Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GHreleasing hormone. J Clin Endocrinol Metab 86:1169-1174
54. Hataya Y, Akamizu T, Takaya K, Kanamoto N, Ariyasu H, Saijo M et al (2001) A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab 86:4552-4555
55. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M et al (2000) Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85:4908-4911
56. Gullett NP, Hebbar G, Ziegler TR (2010) Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 91:1143S-1147S
57. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P et al (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 50:703-713
58. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K et al (2005) Treatment of cachexia with ghrelin in patients with COPD. Chest 128:1187-1193
59. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W et al (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110:3674-3679
60. Akamizu T, Iwakura H, Ariyasu H, Murayama T, Sumi E, Teramukai S et al (2008) Effects of ghrelin treatment on patients undergoing total hip replacement for osteoarthritis: different outcomes from studies in patients with cardiac and pulmonary cachexia. J Am Geriatr Soc 56:2363-2365
61. Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL et al (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649-661
62. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG et al (2004) Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145:2607-2612
63. Hewson AK, Dickson SL (2000) Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 12:1047-1049
64. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA et al (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540-2547
65. Sakata I, Yamazaki M, Inoue K, Hayashi Y, Kangawa K, Sakai T (2003) Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion. Neurosci Lett 342:183-186
66. Chang L, Zhao J, Yang J, Zhang Z, Du J, Tang C (2003) Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol 473:171-176
67. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R et al (2004) Ghrelin inhibits leptin- and activation- induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114:57-66
68. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL et al (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109:2221-2226
69. Wu R, Dong W, Cui X, Zhou M, Simms HH, Ravikumar TS et al (2007) Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 245:480-486
70. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W et al (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104:1430-1435
71. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H et al (2001) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280:R1483-R1487
72. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G et al (1999) Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 22:266-272
73. Enomoto M, Nagaya N, Uematsu M, Okumura H, Nakagawa E, Ono F et al (2003) Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone- releasing peptide, in healthy humans. Clin Sci (Lond) 105:431-435
74. 2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res 79:227-236
75. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghé C et al (2003) Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476:87-95
76. Bedendi I, Gallo MP, Malan D, Levi RC, Alloatti G (2001) Role of endothelial cells in modulation of contractility induced by hexarelin in rat ventricle. Life Sci 69:2189-2201
77. Granata R, Isgaard J, Alloatti G, Ghigo E (2011) Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone- releasing hormone. Exp Biol Med (Maywood) 236:505-514
78. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A et al (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029-1037
79. Nagaya N, Kangawa K (2006) Therapeutic potential of ghrelin in the treatment of heart failure. Drugs 66:439-448
80. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M (2002) Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 40:694-699
81. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M (2004) Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 43:977-982
82. Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada T, Hayashi Y et al (2003) Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 301:275-279
83. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D et al (2005) Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920-2926
84. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C et al (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2832-2836
85. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO (1990) Growth hormone (GH)-releasing peptide stimulates GH release in normal man and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 70:975-982
86. Gertz BJ, Barret JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR et al (1993) Growth hormone response in man to L-692, 429, a novel nonpeptide mimic of growth hormonereleasing peptide. J Clin Endocrinol Metab 77:1393-1397
87. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R et al (1994) Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 78:693-698
88. Svensson J, Lonn L, Jansson JO, Murphy G, Wyss D, Krupa D et al (1998) Two-Month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 83:362-369
89. Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P et al (2003) Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 58:572-580
90. Piccoli F, Degen L, MacLean C, Peter S, Baselgia L, Larsen F et al (2007) Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab 92:1814-1820
91. Palus S, Schur R, Akashi YJ, Bockmeyer B, Datta R, Halem H et al (2011) Ghrelin and its analogues, BIM-28131 and BIM- 28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One 6:e26865
92. Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP et al (2004) The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 52:516-523
93. Garcia JM, Polvino WJ (2007) Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12:594-600
94. Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19:267-273
95. Morozumi N, Hanada T, Habara H, Yamaki A, Furuya M, Nakatsuka T et al (2011) The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats. Peptides 32:1001-1007
96. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo A et al (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120-1128
97. Willesen MG, Kristensen P, Rømer J (1999) Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70:306-316
98. Cremonini F, Camilleri M, Vazquez Roque M, McKinzie S, Burton D, Baxter K et al (2006) Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Gastroenterology 131:1431-1439
99. Laferrère B, Hart AB, Bowers CY (2006) Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring) 14:1056-1063
100. Kumor K, Polvino W (2006) Biologic activity of RC-1291, a novel oral ghrelin mimetic for the treatment of cancer anorexia/ cachexia: results from a phase I randomized, double-blind, placebo-controlled clinical trial in healthy volunteers. Support Care Cancer 14:593
101. Garcia JM, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, doubleblind, crossover, pilot study. Support Care Cancer 21:129-137
102. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM et al (2011) American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 43:1334-1359
103. Dalal HM, Wingham J, Palmer J, Taylor R, Petre C, Lewin R (2012) Why do so few patients with heart failure participate in cardiac rehabilitation? A cross-sectional survey from England, Wales and Northern Ireland. BMJ Open 2:e000787
104. Davies EJ, Moxham T, Rees K, Singh S, Coats AJS, Ebrahim S et al (2010) Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. doi:10.1002/14651858. CD003331.pub3
105. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S et al (2010) Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail 12(7):706-715
106. Downing J, Balady GJ (2011) The role of exercise training in heart failure. J Am Coll Cardiol 58:561-569
107. Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE (2002) Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol 39:1170-1174
108. Simonini A, Long CS, Dudley GA, Yue P, McElhinny J, Massie BM (1996) Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ Res 79:128-136
109. Middlekauff HR (2010) Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 3:537-546
110. Massie BM, Conway M, Rajagopalan B, Yonge R, Frostick S, Ledingham J et al (1988) Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure. Circulation 78:320-326
111. Hambrecht R, Neibauer J, Fiehn E, Kalberer B, Offner B, Hauer K et al (1995) Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 25:1239-1249
112. Adamopoulos S, Coats AJ, Brunotte F, Arnolda L, Meyer T, Thompson CH et al (1993) Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 21:1101-1106
113. Belardinelli R, Georgiou D, Scozzo V, Barstow TJ, Purcaro A (1995) Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol 26:975-982
114. Budgett R (1998) Fatigue and underperformance in athletes: the overtraining syndrome. Br J Sports Med 32:107-110
115. Meadows KA, Holly JM, Stewart CE (2000) Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 183:330-337
116. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ et al (2009) Effects of exercise training on health status in patients with chronic heart failure: hF-ACTION randomized controlled trial. JAMA 301:1451-1459
117. Kilavuori K, Toivonen L, Naveri H, Leinonen H (1995) Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. Eur Heart J 16:490-495
118. Adamopoulos S, Ponikowski P, Cerquetani E, Piepoli M, Rosano G, Sleight P et al (1995) Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. Eur Heart J16:1380-1386
119. Roveda F, Middlekauff HR, Rondon MU, Reis SF, Souza M, Nastari L et al (2003) The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J Am Coll Cardiol 42:854-860
120. Wenger NK, Froelicher ES, Smith LK, Philip A, Ades PA, Berra K et al (1995) Clinical Practice Guidelines No. 17: Cardiac Rehabilitation as Secondary Prevention. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, National Heart, Lung and Blood Institute. AHCPR Publication 96-0672
121. Akashi YJ, Springer J, Anker SD (2005) Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep 2:198-203
122. Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin BA et al (2007) Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 116:572-584
123. Beckers PJ, Denollet J, Possemiers NM, Wuyts FL, Vrints CJ, Conraads VM (2008) Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study. Eur Heart J 29:1858-1866
124. Marimuthu K, Murton AJ, Greenhaff PL (2011) Mechanisms regulating muscle mass during disuse atrophy and rehabilitation in humans. J Appl Physiol 110:555-560
125. Breitbart A, Auger-Messier M, Molkentin JD, Heineke J (2011) Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol 300(6):H1973-H1982
126. Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, Adams V et al (2009) Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 11:342-348